Technology | Stents Peripheral | December 31, 2015

FDA Clears Peripheral Stent from Biotronik

Biotronik Astron stent

December 31, 2015 - The U.S. Food and Drug Administration (FDA) has cleared Biotronik's Astron Peripheral Self-Expanding Nitinol Stent System. The device is indicated for improving luminal diameter in patients with iliac atherosclerotic lesions in vessel reference diameters between 4.3 and 9.5 mm and lesion lengths up to 105 mm. 

The Astron stent system is a self-expanding stent loaded on an over-the-wire delivery system. The stent is laser-cut from a nitinol tube. It carries four radiopaque extensions at each end and is completely coated with amorphous silicon carbide (a-SiC:H). The delivery system consists of two coaxially arranged elements: the inner shaft  and the outer sheath. The inner shaft is made of a thermoplastic polymer. At the proximal end, it is covered with a stainless steel tube. The safety tab that covers the stainless steel tube prevents accidental stent release. The stainless steel tube incorporates a black release marker that indicates the completion of stent deployment and ends with a luer port at the proximal guide wire exit. 

The central guide wire lumen within the inner shaft continues to the radiopaque tip. The stent is mounted between the inner shaft and the outer sheath proximal to the tip, between two radiopaque markers, which facilitate fluoroscopic visualization, and positioning of the delivery system towards and across the lesion. The outer sheath begins within the T-connector and extends towards the tip. It covers the stent and keeps it constrained within its distal end. A hydropholic coating is applied to the inside and outside of the entire outer sheath. The annular space between the inner shaft and the outer sheath can be flushed through the luer port at the T-connector. The guide wire lumen of the inner shaft is flushed through the luer port at the proximal guide wire exit. The guide wire lumen permits the use of 0.035” guide wires to facilitate advancement of the delivery system through the lesion to be treated. The stent system is shipped with an “Easy Release”-tube inserted over the proximal outer sheath. The “Easy Release” tube is intended to be inserted into the hemostatic valve of the introducer to reduce friction between the delivery system and the hemostatic valve during stent release. The stent system and the Easy Release tube are compatible with an appropriately sized introducer sheath according to the indications on the label. The stent is advanced to the intended implantation location by means of the over-the-wire delivery system and is deployed by pulling back the outer sheath at the T-Connector while immobilizing the inner shaft. The stent remains in the vessel as a permanent implant.

The Astron stent is available with fully expanded stent diameters of 7, 8, 9 and 10 mm and stent lengths of 30, 40, 60 and 80 mm. 

Astron self-expanding nitinol stent systems have been market released outside the United States since October 2003. The FDA said the Astron stent system has not been subject to any Field Safety Corrective Action or recall since introduction.

For more information www.biotronik.com

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init